ERBB2 and ductal breast carcinoma in situ: Chapman et al. were the first to assess the frequency of seven autoantibodies (p53, c-Myc, HER2, NY-ESO-1, BRCA1, BRCA2, and MUC1) in a ductal carcinoma in situ (DCIS) population of 40 patients [26].